# ===========================================================================
# Indian API Manufacturer — China+1 Supply Chain Thesis
# ===========================================================================

id: "indian_api_manufacturer_2024"
title: "Indian API Manufacturer — China+1 Supply Chain Thesis"
version: "1.0.0"
type: "ground_truth"
difficulty: "moderate"

ticker: "VDSP"  # NOTE: fictional company (Vedasyn Pharma) to avoid hallucination risk; representative of Indian API/CDMO sector
as_of_date: "2024-07-15"
as_of_context: >
  Vedasyn Pharma (VDSP) is a fictional mid-cap Indian API (active
  pharmaceutical ingredient) and CDMO (contract development and manufacturing
  organization) with approximately $800M in annual revenue and ~25% EBITDA
  margins. The company operates multiple FDA-approved manufacturing
  facilities in Gujarat and Hyderabad. This scenario is representative of
  the Indian API/CDMO sector broadly (companies like Divi's Laboratories,
  Laurus Labs, Shilpa Medicare, PI Industries) rather than any single
  company. The bull thesis centers on the China+1 supply chain
  diversification trend accelerating in pharma. Global pharmaceutical
  companies are actively reducing dependence on Chinese API suppliers due
  to geopolitical risk, quality concerns, and regulatory pressure. The
  US Biosecure Act (introduced in Congress, later signed into law in
  December 2025 as part of the NDAA) specifically targets Chinese biotech companies with ties
  to the Chinese government, creating a structural tailwind for Indian
  manufacturers. India is the world's largest supplier of generic medicines
  and a major API producer, with cost advantages over Western manufacturers
  and improving quality infrastructure. However, the sector faces risks
  including FDA inspection outcomes (several Indian facilities received
  warning letters in 2023-2024), margin pressure from Chinese price
  competition, INR/USD currency volatility, and corporate governance
  concerns at some smaller players.

tags:
  - emerging_markets
  - pharma
  - supply_chain
  - china_plus_one
  - healthcare
  - thematic

# ---------------------------------------------------------------------------
# Ground Truth
# ---------------------------------------------------------------------------
ground_truth:
  expected_direction: 1
  expected_recommendation_bucket: "BUY"
  conviction_range: [4.0, 6.0]
  actual_outcome: >
    The Indian API/CDMO sector performed well through 2024 and into
    2025. The US Biosecure Act was signed into law in December 2025,
    providing a structural catalyst for Indian manufacturers as global
    pharma companies accelerated supply chain diversification away from
    China. Companies like Divi's Laboratories and Laurus Labs saw
    increased order flows and improved visibility on multi-year contracts.
    FDA inspection outcomes remained a stock-specific differentiator, with
    companies maintaining clean compliance records outperforming those with
    regulatory issues. The sector broadly benefited from the thematic
    tailwind, though returns were uneven across individual names depending
    on facility compliance, customer diversification, and margin profiles.
  actual_return_pct: 25.0  # approximate sector return, illustrative
  must_find_facts:
    - "China+1 supply chain diversification trend in pharmaceuticals"
    - "US Biosecure Act targeting Chinese biotech companies"
    - "India as a major global API and generic medicine supplier"
    - "FDA-approved manufacturing facilities as a competitive moat"
    - "approximately 25% EBITDA margins"
    - "cost advantage over Western manufacturers"
  must_find_risks:
    - "FDA inspection risk and recent warning letters at Indian facilities"
    - "margin pressure from Chinese price competition"
    - "INR/USD currency volatility"
    - "corporate governance concerns in emerging market companies"
    - "execution risk in scaling capacity to meet demand"
    - "customer concentration risk if dependent on few large pharma buyers"
    - "regulatory and political risk in India"
  must_not_claim:
    - "the Biosecure Act has already been signed into law as of July 2024"
    - "Chinese API supply has been fully replaced by Indian manufacturers"
    - "FDA inspection risk is immaterial for Indian facilities"
    - "Vedasyn Pharma is a real publicly traded company"
  expert_reasoning_sketch: >
    Moderate-conviction BUY thesis on a structural supply chain shift.
    The China+1 diversification trend in pharma APIs is a multi-year
    secular theme driven by geopolitical tensions, regulatory pressure
    (Biosecure Act), and quality concerns about Chinese manufacturing.
    Indian API/CDMO companies are the primary beneficiaries given their
    existing scale, FDA-approved facilities, and cost positioning. The
    thesis is supported by observable order flow shifts and capacity
    expansion announcements across the sector. However, conviction is
    capped at moderate levels for several reasons: (1) FDA inspection
    risk is real and idiosyncratic — a warning letter can wipe out
    years of commercial progress; (2) Chinese competitors may respond
    with price cuts, compressing margins; (3) emerging market governance
    and accounting transparency remain legitimate concerns; (4) the
    sector is already partially priced for the China+1 theme, limiting
    upside surprise. A well-calibrated committee should recognize the
    structural tailwind while appropriately discounting for the
    execution and regulatory risks inherent in the Indian manufacturing
    sector. This scenario uses a fictional company to test thematic
    analysis capabilities without relying on specific financial data
    that may be hallucinated.

# ---------------------------------------------------------------------------
# Evaluation Criteria
# ---------------------------------------------------------------------------
evaluation_criteria:
  rubric: "committee_standard"
  dimension_overrides: {}
  critical_failures:
    - "Fails to identify China+1 supply chain shift as the primary thesis"
    - "Ignores FDA inspection risk for Indian manufacturers"
    - "Claims Biosecure Act is already law as of July 2024"
    - "Treats Vedasyn Pharma as a real company with verifiable financials"

# ---------------------------------------------------------------------------
# Metadata
# ---------------------------------------------------------------------------
metadata:
  author: "domain_expert"
  created_at: "2026-02-28"
  notes: "Moderate difficulty thematic scenario using a fictional Indian API manufacturer. Tests the system's ability to analyze supply chain themes (China+1), emerging market risks, and sector-level dynamics without relying on specific company financials that could be hallucinated. The fictional ticker VDSP is intentional — the system should analyze the sector thesis rather than attempting to fetch real market data for a nonexistent company."
